Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases
The American Journal of MedicinePublished 1 April 2001
Hans Schepkens, Raymond Vanholder, Jean-Marie Billiouw, Norbert Lameire
Citations259
SJR quartileQ1
SJR score1.00
SNIP1.04
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
Abstract
A combination of ACE inhibitors and spironolactone should be considered with caution and monitored closely in patients with renal insufficiency, diabetes, older age, worsening heart failure, a risk for dehydration, and in combination with other medications that may cause hyperkalemia. A daily spironolactone dose of 25 mg should not be exceeded.
Keywords
MedicineEngineering
New England Journal of MedicineThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
8,985 Citations1999Bertram Pitt, Faı̈ez Zannad +6 more
Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure.
New England Journal of MedicineEffects of Enalapril on Mortality in Severe Congestive Heart Failure
5,077 Citations1987The Consensus Trial Study Group*
It is concluded that the addition of enalapril to conventional therapy in patients with severe congestive heart failure can reduce mortality and improve symptoms and a significant improvement in NYHA classification was observed in the enAlapril group.
The American Journal of CardiologyEffects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
3,778 Citations1988Karl Swedberg, John Kjekshus
The addition of enalapril to conventional therapy in patients with severe congestive heart failure can reduce mortality and improve symptoms, and the effect seems to be due to a reduction in death from progression of heart failure.
The American Journal of CardiologyEffectiveness of Spironolactone Added to an Angiotensin-Converting Enzyme Inhibitor and a Loop Diuretic for Severe Chronic Congestive Heart Failure (The Randomized Aldactone Evaluation Study [RALES])**See Appendix for full list of RALES investigators.
482 Citations1996
Daily doses of 12.5 to 25 mg of spironolactone coadministered with conventional therapy of ACE inhibitors, loop diuretics, and digitalis are relatively safe (provided that serum potassium levels are monitored) and effective in blocking the effects of aldosterone, while reducing the potential for hypokalemia in patients with heart failure.
The American Journal of CardiologySpironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor
170 Citations1993A. van Vliet, A. J. M. Donker +2 more
The 3 patients who were considered refractory to triple therapy exhibited the highest baseline plasma aldosterone concentrations, particularly in the patients who needed spironolactone.
Journal of the American Society of NephrologyHyperkalemia
152 Citations1998I. David Weiner, Charles S. Wingo
Clinical management requires exclusion of pseudohyperkalemia, assessment of the urgency for treatment, and institution of appropriate therapy, and long-term treatment requires identification of the etiology and prevention of recurrence.
JAMAReversible Acute Renal Insufficiency and Hyperkalemia Following Indomethacin Therapy
79 Citations1981Marilyn Galler
Five cases of reversible acute deterioration of renal function in patients with very mild to moderate renal insufficiency who received indomethacin for an acute gouty attack were noted, and hyperkalemia developed in the patients.
Hypertension ResearchEffects of Spironolactone and Angiotensin-Converting Enzyme Inhibitor on Left Ventricular Hypertrophy in Patients with Essential Hypertension.
62 Citations1999Atsuhisa Sato, Yoshiyuki Suzuki +1 more
It is concluded that spironolactone may have beneficial effects on left ventricular hypertrophy in patients with essential hypertension who are receiving an angiotensin-converting enzyme inhibitor.
BMJIncidence of hyperkalaemia induced by indomethacin in a hospital population.
51 Citations1985Ari Zimran, Mark Kramer +2 more
Postgraduate Medical JournalHyperkalaemia in diabetes: prevalence and associations
40 Citations1995Paul Jarman, Anne Kehely +1 more
Serum potassium concentrations were measured in all 1764 patients attending a diabetic clinic over a 12-month period and found to be >5.0 mmol/l in 270 patients, and > 5.4 mmol/L in 67, highlighting the risk of dangerous hyperkalaemia in diabetic patients, particularly with concurrent administration of angiotensin-converting-enzyme inhibitors and potassium-sparing diuretics.
The American Journal of CardiologyAngiotensin-converting enzyme inhibitors and renal function in heart failure
33 Citations1992Rainer Dietz, F Nagel +1 more
Development of functional renal insufficiency is unlikely and is a rare cause for withdrawing ACE inhibitors when certain precautions are considered.
The American Journal of CardiologyCaptopril and spironolactone therapy for refractory congestive heart failure
32 Citations1993Ulf Dahlström, Erling Karlsson
The results suggest that rational therapy for severe CHF includes addition of the aldosterone antagonist spironolactone to low doses of captopril (or another ACE inhibitor) and high doses of loop diuretics, provided renal function is adequate.
The LancetSpironolactone and congestive heart-failure
20 Citations2000Benoît Georges, Claire Beguin +1 more
Postgraduate Medical JournalHyperkalaemia in diabetes mellitus—potential hazards of coexisting hyporeninaemic hypoaldosteronism
18 Citations1984D M Large, Peter Carr +2 more
Investigations demonstrated co-existing hyporeininaemic hypoaldosteronism in two patients with insulin-dependent diabetes mellitus, who developed severe, life-threatening hyperkalaemia following treatment with spironolactone and during treatment for staphylococcal septicaemia.
Nephrology Dialysis TransplantationContinuing nephrological education. Iatrogenic hyperkalaemia-points to consider in diagnosis and management
13 Citations1998K Siamopopulos
Three cases of iatrogenic hyperkalaemia with ECG changes secondary to drug therapy are described and the appropriate sium excretion is discussed, based on these cases, with clinical management of this problem.